12,372 trials
Low Back Pain · Chronic Pain
Primary: The Change in Weekly (ie, 7-day Average) Pain Score at the End of Double-blind, Randomized Treatment Period, Relative to the Weekly Score at the End of Titration…
Dyskinesia · Levodopa Induced Dyskinesia (LID) · Parkinson's Disease (PD)
Primary: Number of Participants With Reported AEs and Safety-Related Study Drug Discontinuations — 57; 70; 23; 55 Participants
Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 14.13; 10.74 Months — p=0.0006
Erosive Esophagitis
Primary: Recovery Rates of Reflux Esophagitis — 101; 92; 126; 43 Participants — p=0.05
Ischemic Stroke · Excitotoxicity · Memantine
Primary: Investigation of Neurological Deficit by National Institute of Health Scale Score (NIHSS) — 4.52; 5.75 score on a scale
Atypical Hemolytic Uremic Syndrome (aHUS)
Primary: Percentage Of Complement Inhibitor Treatment-naïve Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26 — 77.8; 94.4; 88.9; 83.3 percentage of…
Blepharoptosis
Primary: Mean Change From Baseline in Intraocular Pressure (IOP) at Day 84 — -0.6; -0.2; -0.6; -0.2 mmHg
Blepharoptosis
Primary: Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group — 6.3; 2.1; 7.7; 2.4 Points seen — p=<0.0001
Type 1 Diabetes Mellitus
Primary: Change in Hemoglobin A1c (HbA1c) From Baseline — -0.05; -0.06 percent
Allergic Conjunctivitis
Primary: Percentage of Participants With at Least One Adverse Event. — 113; 34 Participants
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2…
Acne Vulgaris
Primary: Mean Percent Change From Baseline to Week 11 (Study Day 77) for Inflammatory (Papules and Pustules) Lesions. — -67.6; -71.3; -51.9 percentage of mean change from baseline
Relapsed Multiple Myeloma · Refractory Multiple Myeloma
Primary: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) — 68; 110; 86; 202 Participants — p=0.0014
Community-acquired Pneumonia (CAP) · Hospital-acquired Pneumonia (HAP)
Primary: Adverse Events — 10; 5; 1; 0 Participants
Pulmonary Arterial Hypertension
Primary: Change From Baseline to Week 26 in Pulmonary Vascular Resistance (PVR) — 0.46; 0.48 ratio — p=0.4239